CIK 0001357874
- Non-accelerated filer
- Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Financial Officer acquired 116,690 shares (option exercise)
- 4 Planned sale President and CEO sold 137,390 shares at $0.36 ($49,460)
- 4 Planned sale General Counsel and Secretary sold 21,287 shares at $0.36 ($7,663)
- 4 Planned sale Chief Medical Officer sold 21,526 shares at $0.36 ($7,749)
- 4 Open-market sale Chief Research Officer sold 28,000 shares at $0.37 ($10,360)
- 4 Planned sale General Counsel and Secretary sold 16,023 shares at $0.40 ($6,409)
- 4 Planned sale President and CEO sold 125,025 shares at $0.40 ($50,010)
- 4 Exercise or conversion Chief Financial Officer acquired 108,188 shares (option exercise)
- 4/A Open-market buy Chief Financial Officer bought 90,000 shares at $0.48 ($43,200)
- 4 Grant or award General Counsel and Secretary acquired 5,443 shares (grant or award)
- 4 Grant or award Chief Research Officer acquired 5,175 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 5,951 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 90,000 shares (grant or award)
- 4 Exercise or conversion VP & Corporate Controller acquired 6,060 shares (option exercise)
- 4 Exercise or conversion Chief Financial Officer acquired 47,726 shares (option exercise)
- 4 Exercise or conversion Chief Research Officer acquired 4,872 shares (option exercise)
- 4 Planned sale General Counsel and Secretary sold 13,361 shares at $0.75 ($10,021)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 6 of 14 · 269 filings